Literature DB >> 33839710

Lung Fibrosis Sequelae After Recovery from COVID-19 Infection.

Agus Dwi Susanto1, Paulus Arka Triyoga2, Fathiyah Isbaniah1, Aulya Fairuz3, Hans Cendikiawan4, Ferdynand Zaron4, Intan Aryanti4, Sarah Naura Irbah3, Moulid Hidayat5.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus diseases 2019 (COVID-19). The SARS-CoV-2 is very contagious and nobody is known to be immune to it. The post-infected lung would leave a scar known as fibrosis, a scar tissue. A study from Wuhan, China suggested the development of fibrosis, though it was too early to label these lung changes as irreversible fibrosis in a time range of 3 weeks. The occurrence of fibrosis indicates a chronic infection which greatly contributes to the hallmark symptom of COVID-19 induced ARDS such as shortness of breath and chest pain. However, many of those studies have not yet explained the condition of the patient's lung after total recovery from the COVID-19. This report demonstrates the clinical symptoms, chest CT scan, spirometry, and blood gas analysis of patient after total recovery from the COVID-19 with appearance lung fibrosis. Copyright (c) 2021 Agus Dwi Susanto, Paulus Arka Triyoga , Fathiyah Isbaniah, Aulya Fairuz, Hans Cendikiawan , Ferdynand Zaron, Intan Aryanti, Sarah Naura Irbah, Moulid Hidayat.

Entities:  

Keywords:  COVID-19; lung fibrosis; recovery

Year:  2021        PMID: 33839710     DOI: 10.3855/jidc.13686

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  2 in total

Review 1.  Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care.

Authors:  Rafal Kopanczyk; Nicolas Kumar; Thomas Papadimos
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-10-03       Impact factor: 2.894

2.  An anti-inflammatory and anti-fibrotic proprietary Chinese medicine nasal spray designated as Allergic Rhinitis Nose Drops (ARND) with potential to prevent SARS-CoV-2 coronavirus infection by targeting RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding.

Authors:  Ka Man Yip; Kwan Ming Lee; Tzi Bun Ng; Shujun Xu; Ken Kin Lam Yung; Shaogang Qu; Allen Ka Loon Cheung; Stephen Cho Wing Sze
Journal:  Chin Med       Date:  2022-07-27       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.